These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 21360108)

  • 1. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
    Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
    Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
    Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
    J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Shimoni A; Zwas ST
    Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
    Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
    Tarella C; Zanni M; Di Nicola M; Patti C; Calvi R; Pescarollo A; Zoli V; Fornari A; Novero D; Cabras A; Stella M; Comino A; Remotti D; Ponzoni M; Caracciolo D; Ladetto M; Magni M; Devizzi L; Rosato R; Boccadoro M; Bregni M; Corradini P; Gallamini A; Majolino I; Mirto S; Gianni AM;
    Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.